PharmaPoint: Dry Eye Syndrome - UK Drug Forecast and Market Analysis to 2022

NEW YORK, Sept. 17, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Dry Eye Syndrome - UK Drug Forecast and Market Analysis to 2022
http://www.reportlinker.com/p01622992/PharmaPoint-Dry-Eye-Syndrome---UK-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

PharmaPoint: Dry Eye Syndrome - UK Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, "PharmaPoint: Dry Eye Syndrome - UK Drug Forecast and Market Analysis to 2022". Dry eye syndrome (DES), or keratoconjunctivitis sicca, is a multifactorial disease of the eye caused by dryness, decreased tear production, or increased tear film evaporation. DES, which is often referred to simply as dry eye, is the most prevalent form of ocular discomfort and irritation. The most common symptoms of DES are ocular irritation and discomfort, foreign body sensation, fatigue, and visual disturbances, which interfere with daily activities. In the elderly population, it is the most common reason for seeking eye care, and this is expected to increase exponentially with an aging demographic.

The DES market in the UK is projected to grow substantially during the forecast period. During the forecast period, the primary growth driver of the DES market in the UK will be the launch of the EU's first prescription product for DES, as well as the rapidly increasing population of DES patients.

Scope

- Overview of the DES including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the UK including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the UK from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the UK DES market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for DES
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in the UK.
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
3 Disease Overview 11
3.1 Etiology and Pathophysiology 11
3.1.1 Etiology 11
3.1.2 Pathophysiology 13
3.1.3 Classification 15
3.1.4 Prognosis 15
3.1.5 Quality of Life 16
3.2 Symptoms 16

4 Disease Management 18
4.1 Overview 18
4.1.1 Diagnosis Overview 18
4.1.2 Treatment Guidelines 20
4.1.3 Treatment Overview 25
4.2 UK 28
4.2.1 Diagnosis 28
4.2.2 Clinical Practice 28
5 Competitive Assessment 29
5.1 Overview 29
5.2 Strategic Competitor Assessment 29
5.3 Product Profiles – Major Brands 31
5.3.1 Restasis (cyclosporine 0.05% ophthalmic emulsion) 31
5.3.2 Additional Therapies 35
6 Opportunity and Unmet Need 39
6.1 Overview 39
6.2 Diagnostic tests are not specific enough to identify subgroups of patients 40
6.3 Frequent dosing and side effects limit compliance 41
6.4 Lack of physician and patient awareness 42
6.5 Trial design may be a factor in so few drugs being approved 43
6.6 Unmet Needs Gap Analysis 44
6.7 Comprehensive method for measuring dry eye signs and severity levels 45
6.8 Increase treatment rates among milder forms of the disease 46
7 Pipeline Assessment 47
7.1 Overview 47
7.2 Promising drugs in clinical development 48
7.2.1 Lifitegrast 49
7.2.2 CF-101 52
7.2.3 Cyclokat 56
8 Market Outlook 60

8.1 United Kingdom 60
8.1.1 Forecast 60
8.1.2 Key Events 62
8.1.3 Drivers and Barriers 62
9 Appendix 64
9.1 Bibliography 64
9.2 Abbreviations 67
9.3 Methodology 69
9.4 Forecasting Methodology 69
9.4.1 Diagnosed DES patients 69
9.4.2 Percent Drug-treated Patients 70
9.4.3 Drugs Included in Each Therapeutic Class 70
9.4.4 Launch and Patent Expiry Dates 70
9.4.5 General Pricing Assumptions 71
9.4.6 Individual Drug Assumptions 72
9.4.7 Generic Erosion 74
9.5 Physicians and Specialists Included in this Study 75
9.6 About the Authors 76
9.6.1 Author 76
9.6.2 Global Head of Healthcare 77
9.7 About GlobalData 78
9.8 Contact Us 78
9.9 Disclaimer 78

1.1 List of Tables

Table 1: Symptoms of Dry Eye Syndrome 17
Table 2: Treatment Guidelines for Dry Eye Syndrome 25
Table 3: Commonly Prescribed Drugs for Dry Eye Syndrome by Class in the Global Markets, 2012 27
Table 4: Leading Treatments for Dry Eye Syndrome, 2012 30
Table 5: Product Profile – Restasis 32
Table 6: Restasis SWOT Analysis, 2012 35
Table 7: Summary of Minor Drug Classes, 2012 38
Table 8: Overall Unmet Needs – Current Level of Attainment 40
Table 9: Clinical Unmet Needs – Gap Analysis, 2012 45
Table 10: Dry Eye Syndrome – Phase Pipeline, 2012 48
Table 11: Comparison of Therapeutic Classes in Development for Dry Eye Syndrome, 2012 49
Table 12: Product Profile – Lifitegrast 50
Table 13: Lifitegrast SWOT Analysis, 2012 52
Table 14: Product Profile – CF101 53
Table 15: CF101 SWOT Analysis, 2012 55
Table 16: Product Profile – Cyclokat 57
Table 17: Cyclokat SWOT Analysis, 2012 59
Table 18: Sales Forecasts ($m) for Dry Eye Syndrome in the United Kingdom, 2012–2022 61
Table 19: Key Events Impacting Sales for Dry Eye Syndrome in the United Kingdom, 2012–2022 62
Table 20: United Kingdom, Dry Eye Syndrome Market – Drivers and Barriers, 2012-2022 62
Table 21: Key Launch Dates 70
Table 22: Key Patent Expiries 70

1.2 List of Figures

Figure 1: Dry Eye Syndrome – Disease Etiology 12
Figure 2: Tear Film in Normal Eye and Dry Eye 13
Figure 3: Sequence of Diagnostic Tests Used to Diagnose Dry Eye Syndrome 18
Figure 4: Delphi Panel Treatment Recommendations for Dysfunctional Tear Syndrome Without Lid Margin Disease, 2006 21
Figure 5: Delphi Panel Treatment Recommendations for Dysfunctional Tear Syndrome With Lid Margin Disease and Abnormal Tear Distribution, 2006 22
Figure 6: Treatment Recommendations for Dry Eye Syndrome from the Management and Therapy Subcommittee, Dry Eye Workshop, 2007 23
Figure 7: American Academy of Ophthalmology Preferred Practice Pattern for Dry Eye, 2011 24
Figure 8: Competitive Assessment of Late-Stage Pipeline Agents in Dry Eye Syndrome, 2012–2022 48
Figure 9: Sales for Dry Eye Syndrome in the United Kingdom by Drug Class, 2012–2022 61

To order this report: PharmaPoint: Dry Eye Syndrome - UK Drug Forecast and Market Analysis to 2022
http://www.reportlinker.com/p01622992/PharmaPoint-Dry-Eye-Syndrome---UK-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker